Walden Group Healthcare M&A Blog

  • Conventus Orthopaedics, Inc. Acquires Flower Orthopedics

    6/2/2020
    Conventus Orthopaedics, developer of a self-expanding nitinol cage technology for repairing fractured wrists, elbows, and shoulders and portfolio company of healthcare investment firm Deerfield Management, has acquired Flower Orthopedics, a maker of disposable, sterile-packed, implant and instrument kits.  Flower complements Conventus’...
    Read More
  • The Walden Group Releases Interim Healthcare Industry Report

    05/27/20
    The Walden Group is pleased to provide access to an Interim Healthcare Industry Report providing a window into how the healthcare industry is taking steps to resume some semblance of normality. It discusses how medical practices and hospitals are carefully opening up, compliant with Covid-19 safety guidelines. It unpacks the effect of the pandemic...
    Read More
  • Select M&A Deals and Terminations in the Age of Coronavirus

    5/18/2020
    Select M&A Deals and Terminations in the Age of Coronavirus (Terms not announced unless specified)     Beaver-Visitec Acquires Ophthalmic Viscoelastic Device Assets from Croma-Pharma (Austria)     Smiths Medical Acquires Access Scientific (US)     Zhuhai Baolian Asset Management Plans to Acquire Shanghai Kehua Bio-Engineering (China)...
    Read More
  • The Walden Group Releases 2020 Q1 Strategic Healthcare M&A Report

    05/04/2020
    The Walden Group, an M&A advisory firm focused on the healthcare industry, has published its complimentary 2020 Q1 Strategic Healthcare M&A Report, available for download on its website, www.waldenmed.com.  The report includes analysis of more than 60 M&A transactions announced of closed in Q1, among several other key developments...
    Read More
  • Big Pharma Invest Deeper into Cancer Treatment

    1/2/2020
    In early December 2019, two of the biggest pharmaceutical companies announced multibillion-dollar deals aiming at bolstering their oncology pipeline.   Merck & Co. Inc. is paying $2.5b to acquire ArQule, Inc, whose lead investigational candidate is an oral Bruton’s tyrosine kinase (BTK) inhibitor currently in a Phase II dose-expansion...
    Read More